Home / Recalls / RXQ Compounding LLC / D-1665-2019

D-1665-2019 Class II Terminated

Recalled by RXQ Compounding LLC — Athens, OH

Recall Details

Product Type
Drugs
Report Date
August 14, 2019
Initiation Date
June 19, 2019
Termination Date
September 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

HYDROMORPHONE 0.2MG/ML IN NACL 0.9% SYR (C-II) , [a) 50 ML NDC 70731-0114-89; b) 55 ML NDC 70731-0114-95] per syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701.

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide USA

Code Information

All lots within expiry

Other recalls by RXQ Compounding LLC

  • D-1653-2019 Class II — EDETATE DISODIUM 15% INJECTABLE, 100 ML per vial, RXQ Compounding, 340 West Stat (June 19, 2019)
  • D-1710-2019 Class II — THIAMINE HCL 100MG/ML (MDV) INJECTION, 10 ML per Vial, RXQ Compounding, 340 West (June 19, 2019)
  • D-1684-2019 Class II — MITOMYCIN 0.04% (PF) OPH SOLN, 1ML per syringe, RXQ Compounding, 340 West State (June 19, 2019)
  • D-1661-2019 Class II — FOLIC ACID 5MG/ML INJECTION SOLUTION (MDV), 10 ML per vial, RXQ Compounding, 340 (June 19, 2019)
  • D-1636-2019 Class II — Ascorbic Acid 500 MG/ML (Non-Corn) INJ (MDV), 50 mL per vial, RXQ Compounding, 3 (June 19, 2019)
  • D-1646-2019 Class II — DEXTROSE 50% INJECTION SOLUTION (PF) SYRINGE, 50 ML per syringe, RXQ Compounding (June 19, 2019)
  • D-1687-2019 Class II — MOXIFLOXACIN 0.5% OPHTH SOLUTION SYRINGE, 1 ML per syringe, RXQ Compounding, 340 (June 19, 2019)
  • D-1689-2019 Class II — NIACINAMIDE 100MG/ML, 10ML per vial, RXQ Compounding, 340 West State Street, Uni (June 19, 2019)
  • D-1681-2019 Class II — MIC B12 W/B6 (LIPOSTAT PLUS) 25/50/50/1/.175 MG/ML, 30 ML per vial, RXQ Compound (June 19, 2019)
  • D-1676-2019 Class II — MANGANESE SULFATE MONOHYDRATE (PFV) 0.1MG/ML INJ, 10 ML per syringe, RXQ Compoun (June 19, 2019)